Chief Business Officer
R. Douglas Armstrong, Ph.D., has over 25 years of life science industry business and finance experience, with emphasis on early stage and emerging growth life science companies. Dr. Armstrong is a seasoned and diverse life science operational and banking executive, including serving as the CEO and Chairman of Aastrom Biosciences and TyraTech, Inc., leading both through initial public offerings, after a tenure as the Executive Vice President of the Sanford Burnham Institute. He specializes in emerging growth development and implementation of capital strategies having personally led capital raises through a variety of public, PIPE and other structured deals, including strategic partnering transactions with capital investment.
Dr. Armstrong has also served at the chairman or board level of multiple public and private life science companies, including the advisory board of a venture capital fund. He is currently a member of the senior management of Dawson James Securities, Inc., and is also a founding partner and president of Auxol Capital, LLC life science investments. Dr. Armstrong holds a Ph.D. degree in Pharmacology from the Medical College of Virginia, and a BA degree in Chemistry from the University of Richmond.